SDGsに焦点を当てた最先端のAIモデルの開発に取り組む株式会社Recursive（代表：ティアゴ・ラマル、所在地：東京都渋谷区、以下Recursive）は、Googleが主催するSDGsの解決に注力しているスタートアップを対象としたメンタリング・プログラム『Advisor Program: SDG ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 08, 2025--(BUSINESS ...

Rallybio Corporation (NASDAQ:RLYB) agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion ...

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

The program originated from a joint venture between the two companies that combined Rallybio’s expertise in HPP research with Recursion’s AI platform. Under the agreement, Rallybio will also receive ...

The company’s partnerships are reportedly advancing, with Recursion receiving an additional $7 million milestone payment from Sanofi (NASDAQ: SNY). This is part of a larger potential deal worth up to ...

Despite these misses, Recursion maintains a strong cash position with $509 million, ensuring operations through mid-2027. The company has been focusing on strategic initiatives, including a merger ...